Здоровье
Australia approves $5.8bn Chemist Warehouse-Sigma Healthcare deal
Australia’s competition regulator on Thursday approved the reverse takeover of Sigma Healthcare by private pharmacy chain Chemist Warehouse, paving the way for the A$8.8 billion
Novo Nordisk is aware of 10 deaths from counterfeit weight loss products
Novo Nordisk on Wednesday the company said it was aware of 10 deaths and 100 hospitalisations as a result of people taking combination copies of
Siemens Healthineers hit full-year revenue and profit forecasts, shares up 8%
Siemens Healthineers on Wednesday the company met forecasts for full-year revenue and profit growth as strength in its imaging segment and U.S. cancer treatment unit
Novo Nordisk lifts restrictions on Wegovy prescriptions in the US, CEO says
Novo Nordisk is lifting prescription restrictions on its weight-loss drug Wegovy in the United States and increasing shipments to that market, its chief executive said
Novartis CEO ‘very confident’ in his sales plans and not afraid of patent collapse
Novartis CEO Vas Narasimhan said in an interview on Saturday that he expects to increase its annual sales by at least 5 per cent a
Novo weight loss drug trial shows improvement in fatty liver disease
Novo Nordisk said Friday that its weight-loss drug achieved the primary goal of a late-stage study in patients with fatty liver disease, reducing scarring of
EU competition authorities to rule on Novo’s purchase of Catalent by 6 December
EU competition authorities will decide by 6 December whether to approve Novo Holdings’ acquisition of contract drugmaker Catalent, the European Commission said in a document
US FDA cautions against California plant making compounded weight-loss drugs
The U.S. Food and Drug Administration on Friday warned against the use of compounded drugs, including versions of popular weight-loss products made at a California
Novo weight loss drug trial shows improvement in fatty liver disease
Novo Nordisk said Friday that its weight-loss drug achieved the primary goal of a late-stage study in patients with fatty liver disease, reducing scarring of
Novartis CEO ‘very confident’ in his sales plans and not afraid of patent collapse
Novartis CEO Vas Narasimhan said in an interview on Saturday that he expects to increase its annual sales by at least 5 per cent a